Floatz logo

Denosumab

Metastatic Neoplasm

Ottawa Hospital Research Institutemonoclonal_antibodyPhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

145 Active assets in the Metastatic Neoplasm cohort.

Asset / SponsorPhaseRating
Xaliplatin
Ruijin Hospital
Phase 4BBB
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
Dexasone
Janssen Research & Development, LLC
Phase 2BBB
Atezolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2/3BB

View all 49 →

Same molecule, other indications

Denosumab is also rated in:

metastatic carcinoma in the boneActive
BBB
Indicative · Phase 4
79 / 100
View asset →
breast carcinomaActive
BB
Indicative · Phase 3
70 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative · Phase 3
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →